News

February 27, 2019

FDA Grants Priority Review to Polatuzumab Vedotin Combo for Difficult-to-treat DLBCL

News

The U.S. Food and Drug Administration has granted priority review to Roche‘s polatuzumab vedotin in combination with Rituxan (rituximab) and the chemotherapy bendamustine for the treatment of patients with relapsed or refractory ... Read more

February 26, 2019

Yescarta Approved in Canada for Adults with Relapsed or Refractory Large B-cell Lymphoma

News

Health Canada has approved Yescarta (axicabtagene ciloleucel) as a treatment for adults with diffuse large B-cell lymphoma (DLBCL) who have already received two or more lines of systemic therapy. Specifically, ... Read more

February 25, 2019

Exposure to Glyphosate in Herbicides Increases Risk of Non-Hodgkin’s Lymphoma, Study Says

News

Exposure to glyphosate, a common broad-spectrum herbicide used worldwide, increases the risk of non-Hodgkin’s lymphoma (NHL) by 41 percent in humans, a study says. The study, “Exposure to Glyphosate-Based Herbicides ... Read more

February 22, 2019

FDA OKs Phase 1 Trial to Test TJC4 in Solid Tumors, Lymphoma

News

I-Mab Biopharma is planning the first-in-human U.S. clinical study evaluating the safety, tolerability, and efficacy of its investigational candidate TJC4 as a treatment for solid tumors and lymphoma. The Phase ... Read more

February 21, 2019

First Patient Dosed in Trial of ADCT-402 for Advanced Non-Hodgkin’s Lymphoma

News

A Phase 1 trial testing the combination of ADCT-402 (loncastuximab tesirine) with Imfinzi (durvalumab) in multiple types of advanced non-Hodgkin’s lymphoma has dosed the first patient. The study (NCT03685344) is for adults with ... Read more

February 19, 2019

Poteligeo Proves Safe, Effective for ATL Patients in Clinical Setting

News

Poteligeo (mogamulizumab), an approved treatment for relapsed or refractory adult T-cell leukemia-lymphoma (ATL) patients in Japan, is also safe and effective in a real-world clinical setting, a postmarketing surveillance study found. ... Read more

February 18, 2019

Opdivo Effective for Relapsed/Refractory Classical Hodgkin’s Lymphoma, Meta-analysis Suggests

News

Immune checkpoint inhibitor Opdivo (nivolumab) appears to be more effective at treating patients with relapsed or refractory classical Hodgkin’s lymphoma than other therapies, a meta-analysis suggests. The study, “Efficacy of ... Read more

February 15, 2019

European Commission Approves Adcetris/Chemo Combo for Some Hodgkin’s

News

The European Commission has approved the used of Adcetris (brentuximab vedotin) in combination with standard chemotherapy for the initial treatment of advanced CD30-positive Hodgkin’s lymphoma patients in the European Union, Norway, Liechtenstein and Iceland. The approval, ... Read more

February 14, 2019

FDA Update Shows 457 Cases of ALCL Linked to Breast Implants

News

The number of reported cases of anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) has risen to 457, according to a 2018 update from the U.S. Food and Drug Administration ... Read more

February 13, 2019February 14, 2019

Stand Up To Cancer’s ‘Dream Team’ to Investigate Devimistat Combo Therapy for T-cell Lymphoma

News

Rafael Pharmaceuticals‘ devimistat (CPI-613) — which targets the metabolic alterations in cancer cells — will be studied as part of a combination therapy for the treatment of T-cell lymphoma, the company announced. ... Read more